Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database
-
Published:2024-09
Issue:9
Volume:30
Page:889-901
-
ISSN:2666-6367
-
Container-title:Transplantation and Cellular Therapy
-
language:en
-
Short-container-title:Transplantation and Cellular Therapy
Author:
Venner Christopher P.ORCID, Duggan Peter, Song Kevin, Reece Donna, Sharma Smriti, Su JiandongORCID, Jimenez-Zepeda Victor H., McCurdy ArleighORCID, Louzada Martha, Mian Hira, Sebag Michael, White DarrellORCID, Stakiw Julie, Kotb Rami, Aslam Muhammad, Reiman Anthony, Gul Engin, Chu Michael P.ORCID, Bergstrom Debra, LeBlanc Richard
Reference22 articles.
1. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma;Child;N Engl J Med,2003 2. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome;Attal;N Engl J Med,1996 3. Autologous transplantation and maintenance therapy in multiple myeloma;Palumbo;N Engl J Med,2014 4. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial;Gay;Lancet Oncol,2015 5. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|